Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1)

Area of Science:

• Endocrinology
• Genetics
• Oncology

Background:

• Multiple Endocrine Neoplasia type 1 (MEN1) is an autosomal dominant disorder caused by mutations in the MEN1 tumor suppressor gene.
• MEN1 is characterized by tumors in the parathyroid, pancreatic islet, and anterior pituitary glands, with potential for other tumors like carcinoids and adrenocortical tumors.
• Patients with MEN1 face reduced life expectancy due to aggressive, multiple, and treatment-resistant tumors, often with metastases.

Purpose of the Study:

• To establish comprehensive guidelines for the evaluation, treatment, and genetic testing of Multiple Endocrine Neoplasia type 1 (MEN1).
• To inform clinical practice regarding the diagnosis and management of MEN1 and its associated tumors.
• To highlight the importance of genetic testing for identifying at-risk family members.

Main Methods:

• Development of guidelines through rigorous review of peer-reviewed publications.
• Involvement of 10 international experts, including physicians, surgeons, and geneticists.
• A multi-stage process of drafting, reviewing, and revising guidelines to ensure consensus.

Main Results:

• MEN1 mutations confer a 50% risk to first-degree relatives, making genetic analysis crucial for early identification.
• MEN1 tumors can be larger, more aggressive, and less responsive to standard treatments compared to sporadic tumors.
• Current treatment outcomes for MEN1 are suboptimal due to disease complexity and tumor characteristics.

Conclusions:

• Presymptomatic tumor detection and MEN1-specific treatments can potentially improve patient prognosis.
• Multidisciplinary team care involving specialists experienced in endocrine tumors is recommended for optimal management of MEN1 patients and their families.
• Genetic testing is vital for family screening and early intervention in hereditary endocrine neoplasia syndromes.